Dr. Dottino on Targeted Therapies in Ovarian Cancer

Peter R. Dottino, MD
Published: Monday, Nov 27, 2017



Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

There are PARP inhibitors and VEGF inhibitors are targeted therapies that are available today, but others are being investigated in phase I/II trials that will be potentially of use, explains Dottino.

According to Dottino in a study investigating p53-mutated patients using AZD1775 with carboplatin in platinum-refractory patients, a 46% response rate was observed.
 


Peter R. Dottino, MD, professor of obstetrics, gynecology and reproductive science, Mount Sinai Hospital, discusses targeted therapies for patients with ovarian cancer.

There are PARP inhibitors and VEGF inhibitors are targeted therapies that are available today, but others are being investigated in phase I/II trials that will be potentially of use, explains Dottino.

According to Dottino in a study investigating p53-mutated patients using AZD1775 with carboplatin in platinum-refractory patients, a 46% response rate was observed.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Publication Bottom Border
Border Publication
x